| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunocytochemistry knockout validation; human; loading ...; fig 2c
| Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher |
- blocking or activating experiments; mouse; 5 ug/ml; loading ...; fig 3b
| Liu Z, Wen J, Wu C, Hu C, Wang J, Bao Q, et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Aging (Albany NY). 2020;12:1213-1236 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3c
| Wang S, Yao F, Lu X, Li Q, Su Z, Lee J, et al. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Am J Cancer Res. 2019;9:1161-1171 pubmed |
- flow cytometry; human; loading ...; fig 3b
| Tong A, Hashem H, Eid S, Allen F, Kingsley D, Huang A. Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncoimmunology. 2017;6:e1303586 pubmed publisher |
- blocking or activating experiments; human; 10 ug/ml; fig 5
| Franzese O, Palermo B, Di Donna C, Sperduti I, Ferraresi V, Stabile H, et al. Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology. 2016;5:e1114203 pubmed publisher |
- blocking or activating experiments; mouse; loading ...; fig 10
| Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher |
- blocking or activating experiments; human; fig 3
- flow cytometry; human
| Deisting W, Raum T, Kufer P, Baeuerle P, Münz M. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE. 2015;10:e0141669 pubmed publisher |
| Akhmetzyanova I, Drabczyk M, Neff C, Gibbert K, Dietze K, Werner T, et al. PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathog. 2015;11:e1005224 pubmed publisher |
- immunohistochemistry - frozen section; human; 1:50; fig 2
| Gulati N, Suárez Fariñas M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher |
- western blot; mouse; 1:500
| Yoon K, Byun S, Kwon E, Hwang S, Chu K, Hiraki M, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015;349:1261669 pubmed publisher |
- blocking or activating experiments; human; fig 4
| Tian X, Zhang A, Qiu C, Wang W, Yang Y, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol. 2015;194:3873-82 pubmed publisher |
- flow cytometry; human; fig 5
| Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher |
| Hautefort A, Girerd B, Montani D, Cohen Kaminsky S, Price L, Lambrecht B, et al. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest. 2015;147:1610-1620 pubmed publisher |
- immunohistochemistry; human
| Gadiot J, Hooijkaas A, Kaiser A, Van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117:2192-201 pubmed publisher |
- immunohistochemistry - frozen section; human; fig 1
- flow cytometry; human
| Raptopoulou A, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 pubmed publisher |
- blocking or activating experiments; human; 10 ug/ml; fig 6
| Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183:4984-93 pubmed publisher |
- flow cytometry; human; tbl 2
| Laudanski K, De A, Miller Graziano C. Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells. Eur J Immunol. 2007;37:2812-24 pubmed |
| Munoz O, Banga R, Schelling R, Procopio F, Mastrangelo A, Nortier P, et al. Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. PLoS Pathog. 2022;18:e1010673 pubmed publisher |
| Zhang G, Jiao Q, Shen C, Song H, Zhang H, Qiu Z, et al. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer. Cancer Sci. 2021;112:997-1010 pubmed publisher |
| Imura Y, Ando M, Kondo T, Ito M, Yoshimura A. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD. JCI Insight. 2020;5: pubmed publisher |
| Okuyama M, Mezawa H, Kawai T, Urashima M. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction. Front Immunol. 2019;10:86 pubmed publisher |
| Guo X, Jiang H, Shi B, Zhou M, Zhang H, Shi Z, et al. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Front Pharmacol. 2018;9:1118 pubmed publisher |
| Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, Yanagihara M, et al. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. Gastric Cancer. 2019;22:486-496 pubmed publisher |
| Rolvering C, Zimmer A, Ginolhac A, Margue C, Kirchmeyer M, Servais F, et al. The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies. J Leukoc Biol. 2018;104:969-985 pubmed publisher |
| Zhao Y, Harrison D, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24:379-390.e6 pubmed publisher |
| Versteven M, Van den Bergh J, Broos K, Fujiki F, Campillo Davó D, De Reu H, et al. A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget. 2018;9:27797-27808 pubmed publisher |
| Martin A, Nirschl C, Polanczyk M, Bell W, Nirschl T, Harris Bookman S, et al. PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget. 2018;9:19177-19191 pubmed publisher |
| Narasimhan P, Akabas L, Tariq S, Huda N, Bennuru S, Sabzevari H, et al. Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion. PLoS Negl Trop Dis. 2018;12:e0006404 pubmed publisher |
| Sun C, Lan P, Han Q, Huang M, Zhang Z, Xu G, et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun. 2018;9:1241 pubmed publisher |
| Zhang L, Xu L, Zhu J, Li J, Xue B, Gao J, et al. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer. Mol Med Rep. 2018;17:7045-7054 pubmed publisher |
| Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16 pubmed publisher |
| De Waele J, Marcq E, Van Audenaerde J, Van Loenhout J, Deben C, Zwaenepoel K, et al. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. Oncoimmunology. 2018;7:e1407899 pubmed publisher |
| Witt D, Donson A, Amani V, Moreira D, Sanford B, Hoffman L, et al. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer. 2018;65:e26960 pubmed publisher |
| Coelho M, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina Arcas M, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47:1083-1099.e6 pubmed publisher |
| Cao J, Brouwer N, Richards K, Marinkovic M, van Duinen S, Hurkmans D, et al. PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget. 2017;8:54722-54734 pubmed publisher |
| Patel S, Sanjana N, Kishton R, Eidizadeh A, Vodnala S, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537-542 pubmed publisher |
| Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher |
| Lazar Molnar E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, et al. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine. 2017;17:30-44 pubmed publisher |
| Fromm J, Thomas A, Wood B. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol. 2017;187:304-317 pubmed publisher |
| Davies L, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. Stem Cells. 2017;35:766-776 pubmed publisher |
| Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-39 pubmed publisher |
| Grenga I, Donahue R, Lepone L, Richards J, Schlom J. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016;5:e83 pubmed publisher |
| Tang Z, Hao Y, Zhang E, Xu C, Zhou Y, Zheng X, et al. CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade. Mol Med Rep. 2016;14:1107-16 pubmed publisher |
| Prebensen C, Lind A, Dyrhol Riise A, Kvale D. Regulation of Gag- and Env-Specific CD8+ T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy. PLoS ONE. 2016;11:e0153849 pubmed publisher |
| Zhang J, Wang C, Zhang P, Wang X, Chen J, Yang J, et al. Expression of programmed death 1 ligand 1 on periodontal tissue cells as a possible protective feedback mechanism against periodontal tissue destruction. Mol Med Rep. 2016;13:2423-30 pubmed publisher |
| Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015;6:43267-80 pubmed publisher |
| Wang W, Yen M, Liu K, Hsu P, Lin M, Chen P, et al. Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. Stem Cell Reports. 2015;5:392-404 pubmed publisher |
| Martin A, Nirschl T, Nirschl C, Francica B, Kochel C, Van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18:325-32 pubmed publisher |
| Görgün G, Samur M, Cowens K, Paula S, Bianchi G, Anderson J, et al. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015;21:4607-18 pubmed publisher |
| Baban B, Liu J, Qin X, Weintraub N, Mozaffari M. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS ONE. 2015;10:e0124059 pubmed publisher |
| Chacon J, Sarnaik A, Chen J, Creasy C, Kale C, Robinson J, et al. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clin Cancer Res. 2015;21:611-21 pubmed publisher |
| Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, et al. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol Lett. 2014;8:1461-1469 pubmed |
| Baral A, Ye H, Jiang P, Yao Y, Mao Y. B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. Oncol Lett. 2014;8:1195-1201 pubmed |
| Braun N, Celada L, Herazo Maya J, Abraham S, Shaginurova G, Sevin C, et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med. 2014;190:560-71 pubmed publisher |
| Tjin E, Krebbers G, Meijlink K, van de Kasteele W, Rosenberg E, Sanders J, et al. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Cancer Immunol Res. 2014;2:538-46 pubmed publisher |
| Quandt D, Jasinski Bergner S, Müller U, Schulze B, Seliger B. Synergistic effects of IL-4 and TNF? on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J Transl Med. 2014;12:151 pubmed publisher |
| Khammari A, Knol A, Nguyen J, Bossard C, Denis M, Pandolfino M, et al. Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res. 2014;2014:186212 pubmed publisher |
| Rabe H, Nordström I, Andersson K, Lundell A, Rudin A. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis. Immunology. 2014;141:467-81 pubmed publisher |
| Pen J, Keersmaecker B, Heirman C, Corthals J, Liechtenstein T, Escors D, et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014;21:262-71 pubmed publisher |
| Legat A, Speiser D, Pircher H, Zehn D, Fuertes Marraco S. Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8?T Cells. Front Immunol. 2013;4:455 pubmed publisher |
| Baglio F, Saresella M, Preti M, Cabinio M, Griffanti L, Marventano I, et al. Neuroinflammation and brain functional disconnection in Alzheimer's disease. Front Aging Neurosci. 2013;5:81 pubmed publisher |
| Maine C, Aziz N, Chatterjee J, Hayford C, Brewig N, Whilding L, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother. 2014;63:215-24 pubmed publisher |
| Seliger B. B7-H abnormalities in melanoma and clinical relevance. Methods Mol Biol. 2014;1102:367-80 pubmed publisher |
| Luheshi N, Davies G, Poon E, Wiggins K, McCourt M, Legg J. Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro. Eur J Immunol. 2014;44:162-72 pubmed publisher |
| Haile S, Dalal S, Clements V, Tamada K, Ostrand Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013;191:2829-36 pubmed publisher |
| Singh A, Mohan A, Dey A, Mitra D. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon ?-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis. 2013;208:603-15 pubmed publisher |
| Bloch O, Crane C, Kaur R, Safaee M, Rutkowski M, Parsa A. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19:3165-75 pubmed publisher |
| Méndez Reguera A, Pérez Montesinos G, Alcántara Hernández M, Martínez Estrada V, Cazarin Barrientos J, Rojas Espinosa O, et al. Pathogenic CCR6+ dendritic cells in the skin lesions of discoid lupus patients: a role for damage-associated molecular patterns. Eur J Dermatol. 2013;23:169-82 pubmed publisher |
| Huang G, Wen Q, Zhao Y, Gao Q, Bai Y. NF-?B plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS ONE. 2013;8:e61602 pubmed publisher |
| Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest. 2013;123:1044-56 pubmed publisher |
| Knol A, Nguyen J, Pandolfino M, Quereux G, Brocard A, Peuvrel L, et al. Tissue biomarkers in melanoma patients treated with TIL. PLoS ONE. 2012;7:e48729 pubmed publisher |
| Singh A, Dey A, Mohan A, Sharma P, Mitra D. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-? producing T cells. PLoS ONE. 2012;7:e44728 pubmed publisher |
| Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, et al. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol. 2013;43:147-58 pubmed publisher |
| Lichtenegger F, Mueller K, Otte B, Beck B, Hiddemann W, Schendel D, et al. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS ONE. 2012;7:e44266 pubmed publisher |
| Daigneault M, de Silva T, Bewley M, Preston J, Marriott H, Mitchell A, et al. Monocytes regulate the mechanism of T-cell death by inducing Fas-mediated apoptosis during bacterial infection. PLoS Pathog. 2012;8:e1002814 pubmed publisher |
| Durand Panteix S, Farhat M, Youlyouz Marfak I, Rouaud P, Ouk Martin C, David A, et al. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol. 2012;189:181-90 pubmed publisher |
| Li Y, Wang J, Li C, Ke X. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma. 2012;53:2015-23 pubmed publisher |
| Ou J, Wiedeman A, Stevens A. TNF-? and TGF-? counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep. 2012;2:295 pubmed publisher |
| Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol. 2012;188:1136-46 pubmed publisher |
| Fujimura T, Ring S, Umansky V, Mahnke K, Enk A. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012;132:1239-46 pubmed publisher |
| Wang B, Bao J, Wang J, Wang Y, Jiang M, Xing M, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011;17:3322-9 pubmed publisher |
| Kozako T, Yoshimitsu M, Akimoto M, White Y, Matsushita K, Soeda S, et al. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders. Hum Immunol. 2011;72:1001-6 pubmed publisher |
| Zheng J, Umikawa M, Zhang S, Huynh H, Silvany R, Chen B, et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell. 2011;9:119-30 pubmed publisher |
| Kim Y, Park S, Broxmeyer H. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. J Immunol. 2011;187:2291-301 pubmed publisher |
| Morbach H, Wiegering V, Richl P, Schwarz T, Suffa N, Eichhorn E, et al. Activated memory B cells may function as antigen-presenting cells in the joints of children with juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:3458-66 pubmed publisher |
| Tjin E, Konijnenberg D, Krebbers G, Mallo H, Drijfhout J, Franken K, et al. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res. 2011;17:5736-47 pubmed publisher |
| Figel A, Brech D, Prinz P, Lettenmeyer U, Eckl J, Turqueti Neves A, et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol. 2011;179:436-51 pubmed publisher |
| Zhao Q, Xiao X, Wu Y, Wei Y, Zhu L, Zhou J, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 2011;41:2314-22 pubmed publisher |
| Schlaphoff V, Lunemann S, Suneetha P, Jaroszewicz J, Grabowski J, Dietz J, et al. Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog. 2011;7:e1002045 pubmed publisher |
| Haile S, Bosch J, Agu N, Zeender A, Somasundaram P, Srivastava M, et al. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol. 2011;186:6822-9 pubmed publisher |
| Andorsky D, Yamada R, Said J, Pinkus G, Betting D, Timmerman J. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232-44 pubmed publisher |
| Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Farina E, et al. A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. Neurobiol Aging. 2012;33:624.e11-22 pubmed publisher |
| Moorman J, Zhang C, Ni L, Ma C, Zhang Y, Wu X, et al. Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses. Vaccine. 2011;29:3169-76 pubmed publisher |
| Frigola X, Inman B, Lohse C, Krco C, Cheville J, Thompson R, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17:1915-23 pubmed publisher |
| Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15:R70 pubmed publisher |
| Banerjee S, Lin C, Skinner K, Schiffhauer L, Peacock J, Hicks D, et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res. 2011;71:318-27 pubmed publisher |
| van de Laar L, van den Bosch A, van der Kooij S, Janssen H, Coffer P, van Kooten C, et al. A nonredundant role for canonical NF-?B in human myeloid dendritic cell development and function. J Immunol. 2010;185:7252-61 pubmed publisher |
| Greenough T, Campellone S, Brody R, Jain S, Sanchez Merino V, Somasundaran M, et al. Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage. PLoS ONE. 2010;5:e12926 pubmed publisher |
| Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher I, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175-86 pubmed publisher |
| Deshpande M, Tipnis S, Shetty P, Ghosh D, Viswanathan C, Majumdar A. Immunologic properties of human dermal fibroblasts. Hum Immunol. 2010;71:1089-98 pubmed publisher |
| Hsu M, Hsiao J, Chang K, Wu Y, Su I, Jin Y, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23:1393-403 pubmed publisher |
| Wu Y, Lin C, Cheng K, Lin C, Wang Y, Lin I, et al. Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection. Clin Exp Immunol. 2010;161:551-9 pubmed publisher |
| Alvarez I, Pasquinelli V, Jurado J, Abbate E, Musella R, de la Barrera S, et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. 2010;202:524-32 pubmed publisher |
| Plege A, Borns K, Beer L, Baars W, Klempnauer J, Schwinzer R. Downregulation of cytolytic activity of human effector cells by transgenic expression of human PD-ligand-1 on porcine target cells. Transpl Int. 2010;23:1293-300 pubmed publisher |
| Kleijwegt F, Laban S, Duinkerken G, Joosten A, Zaldumbide A, Nikolic T, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol. 2010;185:1412-8 pubmed publisher |
| Benson D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286-94 pubmed publisher |
| Bankey P, Banerjee S, Zucchiatti A, De M, Sleem R, Lin C, et al. Cytokine induced expression of programmed death ligands in human neutrophils. Immunol Lett. 2010;129:100-7 pubmed publisher |
| Zhang L, Bertucci A, Ramsey Goldman R, Burt R, Datta S. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol. 2009;183:6346-58 pubmed publisher |
| Kvistborg P, Boegh M, Pedersen A, Claesson M, Zocca M. Fast generation of dendritic cells. Cell Immunol. 2009;260:56-62 pubmed publisher |
| Xie Z, Chen Y, Zhao S, Yang Z, Yao X, Guo S, et al. Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest. 2009;38:624-38 pubmed |
| Pedersen A, Holmstrøm K, Jensen S, Fuchs D, Rasmussen S, Kvistborg P, et al. Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol. 2009;157:48-59 pubmed publisher |
| van Velzen M, Laman J, Kleinjan A, Poot A, Osterhaus A, Verjans G. Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype. J Immunol. 2009;183:2456-61 pubmed publisher |
| Wilcox R, Feldman A, Wada D, Yang Z, Comfere N, Dong H, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114:2149-58 pubmed publisher |
| Zhang Z, Jin B, Zhang J, Xu B, Wang H, Shi M, et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol. 2009;50:1163-73 pubmed publisher |
| Gehring A, Ho Z, Tan A, Aung M, Lee K, Tan K, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682-90 pubmed publisher |
| Fourcade J, Kudela P, Sun Z, Shen H, Land S, Lenzner D, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009;182:5240-9 pubmed publisher |
| Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou L. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009;11:757-66 pubmed publisher |
| Nikolova M, Lelievre J, Carriere M, Bensussan A, Levy Y. Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets. Blood. 2009;113:4556-65 pubmed publisher |
| Gong A, Zhou R, Hu G, Li X, Splinter P, O Hara S, et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol. 2009;182:1325-33 pubmed |
| Bertsias G, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 2009;60:207-18 pubmed publisher |
| Liang M, Yang H, Fu J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett. 2009;276:47-52 pubmed publisher |
| Kinter A, Godbout E, McNally J, Sereti I, Roby G, O Shea M, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181:6738-46 pubmed |
| Wang X, Zhang Z, Zhang S, Fu J, Yao J, Jiao Y, et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur J Immunol. 2008;38:3226-36 pubmed publisher |
| Yang W, Li H, Chen P, Alizadeh H, He Y, Hogan R, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci. 2009;50:273-80 pubmed publisher |
| Zhang J, Zhang Z, Jin B, Zhang S, Zhou C, Fu J, et al. Cutting edge: programmed death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limited hepatitis B virus infection. J Immunol. 2008;181:3741-4 pubmed |
| Butte M, Pena Cruz V, Kim M, Freeman G, Sharpe A. Interaction of human PD-L1 and B7-1. Mol Immunol. 2008;45:3567-72 pubmed publisher |
| Jaehn P, Zaenker K, Schmitz J, Dzionek A. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol. 2008;38:1822-32 pubmed publisher |
| Taglauer E, Trikhacheva A, Slusser J, Petroff M. Expression and function of PDCD1 at the human maternal-fetal interface. Biol Reprod. 2008;79:562-9 pubmed publisher |
| Lafon M, Mégret F, Meuth S, Simon O, Velandia Romero M, Lafage M, et al. Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J Immunol. 2008;180:7506-15 pubmed |
| Yang W, Chen P, Li H, Alizadeh H, Niederkorn J. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008;49:2518-25 pubmed publisher |
| Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57 pubmed publisher |
| Onlamoon N, Rogers K, Mayne A, Pattanapanyasat K, Mori K, Villinger F, et al. Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology. 2008;124:277-93 pubmed publisher |
| Gröschel S, Piggott K, Vaglio A, Ma Krupa W, Singh K, Goronzy J, et al. TLR-mediated induction of negative regulatory ligands on dendritic cells. J Mol Med (Berl). 2008;86:443-55 pubmed publisher |
| Waggoner S, Hall C, Hahn Y. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol. 2007;82:1407-19 pubmed |
| Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer S, Al Tweigeri T, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007;121:751-8 pubmed |
| Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007;178:2763-9 pubmed |
| Petrovas C, Casazza J, Brenchley J, Price D, Gostick E, Adams W, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;203:2281-92 pubmed |
| Ghebeh H, Mohammed S, Al Omair A, Qattan A, Lehe C, Al Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190-8 pubmed |
| Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, et al. Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol. 2006;102:e81-92 pubmed |
| Methe H, Nugent H, Groothuis A, Seifert P, Sayegh M, Edelman E. Matrix embedding alters the immune response against endothelial cells in vitro and in vivo. Circulation. 2005;112:I89-95 pubmed |
| Azam P, Peiffer J, Chamousset D, Tissier M, Bonnet P, Vian L, et al. The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicol Appl Pharmacol. 2006;212:14-23 pubmed |
| Wilmotte R, Burkhardt K, Kindler V, Belkouch M, Dussex G, Tribolet N, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport. 2005;16:1081-5 pubmed |
| Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947-53 pubmed |
